Thursday, January 5, 2012
Academics often lament that pharmas have
shelves full of discontinued compounds that could be useful as research tools
or therapeutics repurposed for new indications. Now, the U.K.'s Medical Research Council has partnered with AstraZeneca plc
to make the pharma's shelved compounds available to academics investigating
basic disease mechanisms.
Osherovich, L. SciBX 5(1);
Published online Jan. 5, 2012
1. Osherovich, L. SciBX 4(45);
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
Cancer Research UK, London, U.K.
Medical Research Council, London, U.K.
Medical Research Council Technology, London, U.K.